Thomas Cahill, MD, PhD, is the founder and managing partner of Newpath Partners, a Boston-based life science venture firm with a mission to translate groundbreaking scientific discoveries into treatments for patients across a broad range of diseases. Newpath creates and builds most of its portfolio companies at the earliest stage of development, working closely with successful entrepreneurial scientists to align their interests with investors, management teams, and employees. Currently, Dr. Cahill is a director at Chroma Medicine, Convergence Therapeutics, Exo Therapeutics, Kisbee Therapeutics, Magnet Biomedicine, Myeloid Therapeutics, Nvelop Therapeutics, Prime Medicine, and YourBio Health. In addition, he is a co-founder of Arena BioWorks, a private research institute located in Cambridge, Massachusetts, where he is a member of the Management Committee. He is also involved with non-profit efforts such as the Personal Genetics Education Project (pgEd). Dr. Cahill received both his MD and PhD from Duke University.